Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Biosimilar Insulins

November 4, 2010

Biosimilar insulins are an interesting, promising field, especially in India and other developing countries. The restrictions by the EMA and FDA are obviously high concerning immunogenicity etc. Biosimilar insulins should lower the high insulin prices. Transgenic plants are particularly a very smart technology.

The second GLP-1-analogliraglutide on the market - comparison with exenatide

February 3, 2010

Analysis of:Novo Nordisk Receives US Approval For Victoza® (liraglutide) For The Treatment Of Type 2 Diabetes | www.medicalnewstoday.com

The advantage of liraglutide is the once daily administration with a long biological halflife. The plasma halflife is longer and therefore the HbA1c-lowering effect pronounced, whereas the postprandial glucose levers are higher compared to exenatide. The LEAD-6-study showed a better HbA1c-lowering with liraglutide however, the comparison was made with twice daily 10 microgram Byetta versus 1.8 mg Victoza, which dose is also licensed.Hopefully the thyroid carcinomas seen in animals will not be found in broader populations in phase-4-studies. Cases of pancreatitis do not seem to occur more frequently with Victoza than in type-2-diabetics without this drug. Future observations will show if one of the two GLP-1-analogues might be preferred in special cases.

Saxagliptin - third gliptin on the EU market

October 8, 2009

Analysis of:ONGLYZA™ (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes | www.pipelinereview.com

Besides Sitagliptin and Vildagliptin there will be now a 3rd gliptin available in Europe. Whereas vildagliptin officially needs monitoring of the liver enzymes, at least according to the P.I., and there are new warnings for pancreatitis for sitagliptin no such limitations are known to me at the moment. I do not think that there will be major advantages for saxa compared with sita or vilda, however, we will have to wait and see.

Life-extending effect of Byetta ?

August 13, 2008

Analysis of:Lilly Diabetes Drug Shows a Life-Extending Promise | www.nytimes.com

In a small subgroup of type-2-diabetes patients in the ACCORD trial which had been treated with Byetta (825 of 10 000) a lowerde death rate was found as compared to the whole group. This is a hypothesis-generating finding. Fewer hypoglycemias, even mild ones, may be an exüplanation for this result which, however, awaits bigger studies planned to answer this question

A new gliptin - what is the difference to sita- and vildagliptin?

July 29, 2008

Analysis of:AstraZeneca and Bristol-Myers Squibb Submit New Drug Application in the United States and Marketing Authorisation Application in Europe for ONGLYZA™ (Saxagliptin) for the Treatment of Type 2 Diabetes | www.astrazeneca.com

As the member of an Advisory board for a gliptin ande not familiar with details on saxagliptin it would be interested to know what makes the difference to the gliptins already on the US and EU market. How is the DPP-4-specifity? Only for DDP-4 or also somewhat for DPP-9? Or other DPP´s ? What´s on with the transaminases? How often a day should it be given? Any other than sita- and vildagliptin regarding weight - only "neutral"?

Page : 11 to 5 of 5

Subscribe to Updates

By RSS